The round was led by Israel's preeminent Venture fund TechAviv, and joined by renowned Austin-based VCs Next Coast Ventures, Trust Ventures and Texas Venture Partners as well as NY-based Lerer Hippeau and others. The funds will be used to continue development of Somite's proprietary AlphaStem AI platform, building Somite labs and bringing the first therapeutic asset to phase 1 clinical trials.

这一轮由以色列卓越的风险投资基金TechAviv牵头，著名的奥斯汀风险投资公司Next Coast Ventures、Trust Ventures和德克萨斯风险投资合作伙伴以及纽约的Lerer Hippeau等加入。这些资金将用于继续开发Somite专有的AlphaStem AI平台，建设Somite实验室，并将第一个治疗资产带入第一阶段临床试验。

Somite.ai is a venture-backed company aiming to become the OpenAI of stem cell biology, developing AI foundation models to produce human tissue for cell therapies at scale for diseases such as diabetes, obesity, and muscular dystrophies. Somite's AI platform, AlphaStem, fuels a virtuous cycle: It enables new cell therapies, generating massive data that further improve the platform, empowering even faster therapy creation with broader applications..

Somite.ai是一家由风险投资支持的公司，旨在成为干细胞生物学的开放式人工智能，开发人工智能基金会模型，以生产人体组织，用于大规模治疗糖尿病，肥胖症和肌肉营养不良等疾病的细胞治疗。Somite的人工智能平台AlphaStem促进了一个良性循环：它可以实现新的细胞疗法，产生大量数据，进一步改进平台，使更广泛的应用能够更快地创建疗法。